Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Core Insights - Annexon, Inc. has appointed Dr. Lloyd Clark as senior vice president of ophthalmology strategy and innovation, bringing over 25 years of experience in retina diseases and drug development [1][3] - The investigational therapy ANX007 is the only treatment shown to significantly preserve vision and central retinal photoreceptors in patients with dry age-related macular degeneration (AMD) with geographic atrophy (GA) [2][3] - The Phase 3 ARCHER II trial for ANX007 is expected to complete enrollment by Q3 2025, with topline data anticipated in the second half of 2026 [2][6] Company Overview - Annexon, Inc. focuses on developing novel therapies for neuroinflammatory diseases, targeting the classical complement pathway to prevent tissue damage [7] - The company aims to address significant unmet needs in the treatment of neurodegenerative and ophthalmic diseases, with a pipeline that includes investigational drug candidates for over 8 million patients globally [7] Product Details - ANX007 is designed to block C1q locally in the eye and is currently being evaluated in the pivotal Phase 3 ARCHER II trial, which will enroll approximately 630 patients [2][6] - The primary endpoint of the ARCHER II trial is to prevent a ≥15-letter loss in best corrected visual acuity (BCVA), a well-established functional endpoint for ophthalmology drug approvals [6] Market Context - Dry AMD with GA is a leading cause of blindness affecting over 8 million patients worldwide, with no approved therapies currently available to preserve vision [2][4] - The addition of Dr. Clark to the Annexon team is seen as a strategic move to enhance the company's position in the retina community and improve treatment options for patients with dry AMD [3]